“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.2B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively. Investment risks include: (1) failure of drug candidates in clinical trials; (2) failure of drug candidates to secure regulatory approval; (3) failure of drug candidates to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential dilution risk.”,” the firm’s analyst wrote.
A number of other equities analysts have also issued reports on STML. BidaskClub raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 14th. ValuEngine raised shares of Stemline Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 14th. Zacks Investment Research raised shares of Stemline Therapeutics from a sell rating to a hold rating in a report on Thursday, August 16th. Wedbush reaffirmed an outperform rating and set a $22.00 target price on shares of Stemline Therapeutics in a report on Monday, November 12th. Finally, Roth Capital set a $33.00 target price on shares of Stemline Therapeutics and gave the company a buy rating in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $26.32.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06). As a group, equities analysts predict that Stemline Therapeutics will post -2.8 earnings per share for the current fiscal year.
In other news, COO Kenneth Hoberman sold 26,296 shares of Stemline Therapeutics stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.80% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. grew its stake in Stemline Therapeutics by 17.9% in the 2nd quarter. BlackRock Inc. now owns 1,852,820 shares of the biopharmaceutical company’s stock valued at $29,739,000 after acquiring an additional 281,394 shares during the period. Millennium Management LLC grew its stake in Stemline Therapeutics by 169.3% in the 2nd quarter. Millennium Management LLC now owns 161,735 shares of the biopharmaceutical company’s stock valued at $2,596,000 after acquiring an additional 101,679 shares during the period. Point72 Asset Management L.P. grew its stake in Stemline Therapeutics by 20.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock valued at $4,316,000 after acquiring an additional 45,000 shares during the period. Northern Trust Corp grew its stake in Stemline Therapeutics by 12.5% in the 2nd quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock valued at $6,106,000 after acquiring an additional 42,262 shares during the period. Finally, Nexthera Capital LP grew its stake in Stemline Therapeutics by 6.9% in the 2nd quarter. Nexthera Capital LP now owns 559,517 shares of the biopharmaceutical company’s stock valued at $8,980,000 after acquiring an additional 35,893 shares during the period. 64.20% of the stock is owned by hedge funds and other institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Read More: What are catch-up contributions?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.